Human Insulin Drug Is Administered To Patients Suffering From Diabetes and Related Complications

Human Insulin Drug

Human Insulin Drug is a life-saving medication that has revolutionized the treatment of diabetes, a chronic metabolic disorder characterized by high blood sugar levels. This remarkable drug, developed through advancements in biotechnology, has transformed the lives of millions of individuals worldwide, enabling them to effectively manage their condition and improve their quality of life.

The global Human Insulin Drug Market was valued at US$ 42,283.9 Mn in 2021 and is forecast to reach a value of US$ 73,127.2 Mn by 2028 at a CAGR of 8.1% between 2022 and 2028.

Before the introduction of human insulin medicine therapy, individuals with diabetes faced a bleak prognosis, as the only available treatments were restrictive diets that offered limited control over blood sugar levels. Insulin therapy, derived initially from animal sources, provided a groundbreaking solution, allowing for the replacement of the deficient insulin in the body.

However, with the advancement of biotechnology and genetic engineering, the production of human insulin medicines became possible. A Human Insulin Drug is a synthetic form of insulin that is identical to the insulin naturally produced by the human body. This significant development eliminated the need for animal-derived insulin, minimizing the risk of allergic reactions and ensuring a more reliable supply.

The production of human insulin medicines involves recombinant DNA technology. The human insulin gene is inserted into host organisms such as yeast or bacteria, which act as factories for the production of insulin. The host organisms are engineered to produce insulin protein that is structurally and functionally identical to human insulin. After the production process, the insulin protein is purified to remove impurities, resulting in a safe and effective drug for clinical use.

There are different types of Human Insulin Drug available to meet the diverse needs of individuals with diabetes. These types include rapid-acting insulin, short-acting insulin, intermediate-acting insulin, and long-acting insulin. Each type has a distinct onset, peak, and duration of action, allowing for flexible and personalized diabetes management.

Rapid-acting human insulin medicines, such as insulin aspart and insulin lispro, start working within 15 minutes after injection, with their peak effect occurring within 1-2 hours. Short-acting insulin, such as regular insulin, takes effect within 30 minutes, peaking between 2-3 hours after injection. Intermediate-acting insulin, such as NPH insulin, has a delayed onset of action and a longer duration of effect, typically lasting up to 12-16 hours. Long-acting insulin, such as insulin glargine and insulin detemir, has a slow and consistent release, providing a stable basal insulin level for approximately 24 hours.

The benefits of Human Insulin Drugs are significant. Firstly, human insulin allows for more precise glycemic control, helping individuals with diabetes achieve target blood sugar levels. This control minimizes the risk of acute complications such as hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar), promoting overall well-being and reducing long-term complications.

Human insulin medicine also provides a more predictable and consistent supply compared to animal-derived insulins. The mass production and standardization of human insulin ensure a reliable and readily available drug for individuals with diabetes worldwide. This accessibility is crucial in improving patient outcomes and reducing health disparities.